A preclinical study evaluated whether NGF gene transfer could mitigate the onset and progression of diabetic cardiomyopathy (DCM) in a murine model of STZ-induced diabetes, compared to non-diabetic controls. The gene discussed is NGF; the disease is diabetic cardiomyopathy.